Pharming Intellectual Property B.V. v. Pharmington Pharma Limited Liability Company, dedc:1:2022cv01325

pharmaceutical products for the treatment of hereditary angioedema, also referred to as HAE;

pharmaceutical products for the treatment of hereditary angioedema, also referred to as HAE;

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, genetic disorders and immune system related diseases and disorders;

Pharmaceutical preparations and substances for the treatment of viral, [ metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, ] oncological, [ hepatological, ophthalmic, ] respiratory, neurological, gastrointestinal, hormonal, [ dermatological, psychiatric, ] genetic disorders and immune system related diseases and disorders;

Pharmaceutical preparations and substances for the treatment of viral, [ metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, ] oncological, [ hepatological, ophthalmic, ] respiratory, neurological, gastrointestinal, hormonal, [ dermatological, psychiatric, ] genetic disorders and immune system related diseases and disorders [, except not including pharmaceutical preparations to treat or prevent obesity; pharmaceutical preparations for weight management, weight loss and the maintenance of weight loss; pharmaceutical preparations for the treatment and prevention of diabetes; pharmaceutical preparations for the promotion of smoking cessation; pharmaceutical preparations for the treatment and prevention of drug and alcohol abuse ];